antioxidants Article Reevaluation of Serum Arylesterase Activity in Neurodevelopmental Disorders Ignazio Stefano Piras 1,2, Stefano Gabriele 1, Laura Altieri 1, Federica Lombardi 1, Roberto Sacco 1, Carla Lintas 1 , Barbara Manzi 3, Paolo Curatolo 3, Maria Nobile 4, Catia Rigoletto 4, Massimo Molteni 4 and Antonio M. Persico 5,* 1 Unit of Child & Adolescent Neuropsychiatry, University Campus Bio-Medico, I-00128 Rome, Italy;
[email protected] (I.S.P.);
[email protected] (S.G.);
[email protected] (L.A.);
[email protected] (F.L.);
[email protected] (R.S.);
[email protected] (C.L.) 2 Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, AZ 85254, USA 3 Unit of Child and Adolescent Neuropsychiatry, University of Rome “Tor Vergata”, I-00133 Rome, Italy;
[email protected] (B.M.);
[email protected] (P.C.) 4 Child Psychopathology Unit, Scientific Institute, IRCCS ‘E. Medea’, I-23842 Bosisio Parini (LC), Italy;
[email protected] (M.N.);
[email protected] (C.R.);
[email protected] (M.M.) 5 Interdepartmental Program “Autism 0–90”, “G. Martino” University Hospital, University of Messina, I-98122 Messina, Italy * Correspondence:
[email protected] Abstract: Organophosphate compounds (OPs) interfere with neurodevelopment and are neuro- toxic for humans and animals. They are first biotransformed to the more toxic oxon form, and then hydrolyzed to specific metabolites by the enzyme paraoxonase/arylesterase, encoded by the gene PON1 located on human chr. 7q21.3. In autism spectrum disorder (ASD) and in attention- deficit/hyperactivity disorder (ADHD), a correlation between OP exposure and disease onset has Citation: Piras, I.S.; Gabriele, S.; been reported.